Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Veru Inc (VERU)

Veru Inc (VERU)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 95,018
  • Shares Outstanding, K 146,384
  • Annual Sales, $ 16,300 K
  • Annual Income, $ -93,090 K
  • EBIT $ -52 M
  • EBITDA $ -52 M
  • 60-Month Beta -0.50
  • Price/Sales 5.63
  • Price/Cash Flow N/A
  • Price/Book 2.85
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.39
  • Most Recent Earnings $-0.06 on 12/16/24
  • Next Earnings Date 12/13/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend 0.070 on 04/28/14
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 426.39% ( +90.07%)
  • Historical Volatility 73.90%
  • IV Percentile 81%
  • IV Rank 27.86%
  • IV High 1,390.40% on 02/13/24
  • IV Low 54.07% on 10/21/24
  • Put/Call Vol Ratio 0.96
  • Today's Volume 1,318
  • Volume Avg (30-Day) 1,040
  • Put/Call OI Ratio 0.43
  • Today's Open Interest 36,073
  • Open Int (30-Day) 35,417

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.08
  • Number of Estimates 4
  • High Estimate -0.07
  • Low Estimate -0.09
  • Prior Year -0.09
  • Growth Rate Est. (year over year) +11.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6000 +8.18%
on 12/19/24
0.8174 -20.59%
on 12/16/24
+0.0238 (+3.81%)
since 11/20/24
3-Month
0.5750 +12.89%
on 11/18/24
0.9990 -35.03%
on 10/14/24
-0.1307 (-16.76%)
since 09/20/24
52-Week
0.3600 +80.31%
on 01/22/24
1.9200 -66.19%
on 04/11/24
-0.0245 (-3.64%)
since 12/20/23

Most Recent Stories

More News
Veru Inc. to Present at 17th International Conference on Sarcopenia, Cachexia, & Wasting Disorders

Veru Inc. will present on improving GLP-1 RA weight loss drugs at an upcoming conference in Washington, DC.Quiver AI SummaryVeru Inc. has announced its participation in the 17th International Conference...

VERU : 0.6491 (+3.20%)
Veru to Present at the 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders

VERU : 0.6491 (+3.20%)
Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeek

VERU : 0.6491 (+3.20%)
Veru to Present at ObesityWeek: Meta-Analysis of 4 Previous Randomized Clinical Trials that Support the Potential of Enobosarm to Optimize Weight Loss

VERU : 0.6491 (+3.20%)
Veru to Deliver Keynote Presentation on the Scientific Support for Enobosarm in Combination with GLP-1 Receptor Agonist to Preserve Muscle for Higher Quality Weight Loss at the 4th Edition of the World Obesity and Weight Management Congress

VERU : 0.6491 (+3.20%)
Rapid Advancements of Innovative Antiviral – COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market

EQNX::TICKER_START (NYSE:NNVC),(NASDAQ:BCRX),(NASDAQ:VERU),(NASDAQ:CMRX),(NASDAQ:SIGA) EQNX::TICKER_END

BCRX : 7.57 (+2.44%)
NNVC : 1.4900 (+2.76%)
VERU : 0.6491 (+3.20%)
CMRX : 2.99 (+4.91%)
SIGA : 5.91 (-1.99%)
Rapid Advancements of Innovative Antiviral – COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market

NNVC : 1.4900 (+2.76%)
VERU : 0.6491 (+3.20%)
CMRX : 2.99 (+4.91%)
SIGA : 5.91 (-1.99%)
3 Standout Penny Stocks to Watch This April

Investing in penny stocks carries substantial risk, but also offers the potential for significant returns. These penny stocks, all with bullish analyst ratings, have considerable upside potential, according...

OCGN : 0.7743 (+0.83%)
VERU : 0.6491 (+3.20%)
DM : 2.85 (-8.06%)
$SPX : 5,930.85 (+1.09%)
Stock Index Futures Move Higher As Dovish Fed Comments Boost Hopes Of Fed Pivot

March S&P 500 futures (ESH23) are up +0.21%, and March Nasdaq 100 E-Mini futures (NQH23) are up +0.34% this morning after three major U.S. benchmark indices closed higher on Thursday as investors cheered...

ESH23 : 3,957.05s (-0.09%)
NQH25 : 21,632.00 (+0.30%)
CRM : 343.65 (+2.21%)
TSLA : 421.06 (-3.46%)
LHA.D.DX : 6.201 (+0.86%)
AI : 36.34 (+2.51%)
VERU : 0.6491 (+3.20%)
CHPT : 1.2400 (+8.77%)
COST : 954.07 (-0.08%)
MRVL : 111.90 (+2.56%)
Final Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Veru Inc. (VERU) Investors of Class Action and to Actively Participate

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Veru Inc. (“Veru” or the “Company”) (NASDAQ: VERU) and certain of...

VERU : 0.6491 (+3.20%)

Business Summary

Veru Inc. engages in the development, manufacture and marketing of consumer health care products. It focuses on producing FC2 female condom which provides dual protection against unintended pregnancy and sexually transmitted infections. Veru Inc., formerly known as The Female Health Company, is headquartered...

See More

Key Turning Points

3rd Resistance Point 0.7326
2nd Resistance Point 0.7082
1st Resistance Point 0.6787
Last Price 0.6491
1st Support Level 0.6248
2nd Support Level 0.6004
3rd Support Level 0.5709

See More

52-Week High 1.9200
Fibonacci 61.8% 1.3241
Fibonacci 50% 1.1400
Fibonacci 38.2% 0.9559
Last Price 0.6491
52-Week Low 0.3600

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar